Mednax, Inc.

Find Ratings Reports
MD : NYSE :
$67.84 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 0
03/22/17 - 4:02 PM ET

Financial Analysis


MEDNAX INC's gross profit margin for the fourth quarter of its fiscal year 2016 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased. MEDNAX INC has average liquidity. Currently, the Quick Ratio is 1.25 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

During the same period, stockholders' equity ("net worth") has increased by 13.26% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)830.77741.74
EBITDA ($mil)168.03170.11
EBIT ($mil)142.78151.96
Net Income ($mil)78.0892.7


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)66.9860.43
Total Assets ($mil)5339.44547.21
Total Debt ($mil)1705.681274.7
Equity ($mil)2760.772437.53


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin31.9134.45
EBITDA Margin20.2222.93
Operating Margin17.1920.49
Sales Turnover0.60.61
Return on Assets6.087.39
Return on Equity11.7613.79
Debt Q4 FY16 Q4 FY15
Current Ratio1.311.23
Debt/Capital0.380.34
Interest Expense16.368.49
Interest Coverage8.7317.89


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)93.7293.74
Div / share0.00.0
EPS0.840.99
Book value / share29.4626.0
Institutional Own % n/a n/a
Avg Daily Volume704671.0649754.0

Valuation


BUY. This stock's P/E ratio indicates a discount compared to an average of 28.96 for the Health Care Providers & Services industry and a discount compared to the S&P 500 average of 26.73. For additional comparison, its price-to-book ratio of 2.37 indicates a discount versus the S&P 500 average of 2.98 and a discount versus the industry average of 3.42. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly above the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, MEDNAX INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MD 19.93 Peers 28.96   MD 14.73 Peers 12.72

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

MD is trading at a significant discount to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MD is trading at a premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MD 15.03 Peers 16.02   MD 0.92 Peers 1.25

Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.

MD is trading at a valuation on par with its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MD trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MD 2.37 Peers 3.42   MD -2.24 Peers 19.88

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MD is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MD is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MD 2.05 Peers 0.87   MD 14.50 Peers 11.77

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MD is trading at a significant premium to its industry.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

MD has a sales growth rate that exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades